Argenx posts Q3 2026 sales of $1.7 billion, 54% YoY growth, and outlines 2027 launch pipeline

Argenx reported third‑quarter 2026 product net sales of $1.7 billion, a 54% year‑over‑year increase driven by VYVGART. Net income was $506 million and earnings per share were $7.80. The company said Phase 3 data for empasiprubart are expected in December 2026 and that FB102 will move to Phase 3 in celiac disease, while it plans to file an sBLA for VYVGART Hytrulo in IMNM by year‑end. It also highlighted a $2.2 billion acquisition of Forte Biosciences that raises 2026 R&D and SG&A spending to about $4 billion.

The sales surge confirms strong demand for VYVGART, supporting revenue growth expectations for 2027. However, higher operating costs from the Forte deal and the $4 billion expense outlook compress margins, meaning investors should watch expense trends and upcoming data readouts for empasiprubart and FB102.

  • 1Product net sales were $1.7 billion in Q3 2026, up 54% year‑over‑year.
  • 2Net income was $506 million in Q3 2026.
  • 3Earnings per share were $7.80 in Q3 2026.
  • 4Phase 3 data for empasiprubart are expected in December 2026.
  • 5FB102 will advance to Phase 3 in celiac disease.
  • 6The company plans to submit an sBLA for VYVGART Hytrulo in IMNM by year‑end 2026.

Sources